The Jynneos vaccine from Bavarian Nordic A/S (OMX:BAVA), the most widely used vaccine to protect against monkeypox, tends to have generally mild side effects according to clinical trial data. It is also clear that the Jynneos vaccine can help reduce the severity of monkeypox infections. Researchers are uncertain, however, about how the vaccine’s potential to…
EMA emergency task force backs intradermal use of Imvanex/Jynneos monkeypox vaccine
EMA’s Emergency Task Force (ETF) has given national authorities in the EU permission to use the Imvanex vaccine as an intradermal injection while supplies of the vaccine remain limited. In a statement, the ETF described the decision as a “temporary measure.” The FDA recently reached a similar decision but authorized the intradermal use of the Imvanex…
Jynneos vaccine: The best weapon against monkeypox?
Over the past few months, healthcare leaders have been working on identifying vaccines to prevent the spread of monkeypox. One such development is the use of Bavarian Nordic’s (OMX:BAVA) Jynneos vaccine for the prevention and treatment of the fast-spreading disease. The Jynneos vaccine won approval in the U.S. in 2019 for the prevention of monkeypox…
3 critical monkeypox vaccine questions
In the U.S., federal authorities have allowed two vaccines to be used to reduce the risk of monkeypox virus infection. The preferred option is the Jynneos vaccine from Bavarian Nordic (OMX:BAVA), followed by Emergent BioSolutions’ (NYSE:EBS) ACAM2000. While vaccination efforts are ramping up, California, New York and Illinois have declared states of emergency as the…
FDA greenlights 786,000 additional monkeypox vaccine doses
FDA has signed off on a supplement to the biologics license for Bavarian Nordic’s (OTCMKTS:BVNRY) Jynneos vaccine, which is indicated for both monkeypox and smallpox. The move will make an additional 786,000 doses of vaccine available for use in the U.S. The extra doses are available following an FDA expedited inspection and approval of Bavarian…
U.S. purchases more monkeypox vaccine doses from Bavarian Nordic
Bavarian Nordic A/S (OMX:BAVA) has announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) has ordered an additional 2.5 million doses of liquid-frozen Jynneos vaccine. FDA first approved Jynneos, a non-replicating smallpox and monkeypox vaccine, in 2019. It continues to be the only FDA-approved vaccine indicated for monkeypox. The company will begin deliveries…